Journal profile · Medicine-Oncology
Exploration of Targeted Antitumor Therapy
ISSN 2692-3114 · Open Exploration Publishing Inc. · China
Exploration of Targeted Antitumor Therapy: fully open access; APC about USD 2,000; median 101 days to acceptance (96 articles, last 24 months); acceptance rate 33% (journal website); 71 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Exploration of Targeted Antitumor Therapy is published by Open Exploration Publishing Inc.. By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations and Cancer Genomics and Diagnostics, together about 31.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Exploration of Targeted Anti-tumor Therapy (eISSN 2692-3114), a peer-reviewed, open access online journal, publishes articles on all aspects of cancer research, including clinical diagnosis and analysis, case report, prevention, intervention treatment, pre-clinical and clinical trials of all types of cancers. Submissions with good originality, well-designed experiments and rigorous data are particularly welcomed.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editorial board by country: 12 in mainland China (about 18%); most named Italy 21, Mainland China 12, United Kingdom 7, United States 4, Spain 4 (65 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine16.6%
- Lung Cancer Treatments and MutationsMedicine8.5%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology6.8%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology6.6%
- Lung Cancer Diagnosis and TreatmentMedicine5.2%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.8%
- Cancer Cells and MetastasisMedicine4.1%
- Glioma Diagnosis and TreatmentMedicine3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Oncology | Q2 | 140/428 | — |
| Cancer Research | Q2 | 115/233 | — |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 5.4LetPub ·
- CiteScore (publisher)
- 5.4Publisher website ·
- SJR 2026-06
- 0.88LetPub ·
- SNIP 2026-06
- 0.69LetPub ·
- h-index
- 28OpenAlex ·
- i10-index
- 139OpenAlex ·
- 2-year mean citedness
- 6.01OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year (publisher) 2026
- 2,026Publisher website ·
- Articles per year (publisher) 2025
- 1Publisher website ·
- Articles per year (publisher) 2024
- 5Publisher website ·
- Articles per year (publisher) 2023
- 4Publisher website ·
- Articles per year (publisher) 2022
- 6Publisher website ·
- Articles per year (publisher) 2021
- 5Publisher website ·
- Articles per year (publisher) 2020
- 9Publisher website ·
- Downloads per year (publisher)
- 36,721Publisher website ·
Articles by year OpenAlex count · 413 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 55 | 55 | 1,397 |
| 2025 | 71 | 71 | 1,387 |
| 2024 | 84 | 84 | 786 |
| 2023 | 83 | 83 | 428 |
| 2022 | 50 | 50 | 172 |
| 2021 | 40 | 40 | 67 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
101 daysMedian, submission to acceptance · P25–P75 76 days – 121 days
- Acceptance to online
- median 27 days (96 articles)
- Submission to online
- median 130 days
- Sample
- 96 articles with submission and acceptance dates (133 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 13 weeksLetPub ·
- Acceptance rate (publisher)
- 33%Publisher website ·
- Submission to first decision
- 11 daysPublisher website ·
- Acceptance to publication
- 22 daysPublisher website ·
- Submission to publication (journal-reported)
- about 13 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,000 | Yes | CC BY | |
| LetPub | No APC | No | — | |
| Publisher website | USD 2,000 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 300 words
- Keywords
- 3–8
- Manuscript length
- ≤ 3,000 words
- Reference style
- Vancouver
- Templates
- Word
- Suggested reviewers
- Optional
- Cover letter
- Required
Article types accepted11, with length limits
- case reportThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
- commentaryThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
- editorialThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
- letter to the editorThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
- meta-analysisThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
- original articleThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
- perspectiveords 3-8 N/A ≤ 3000 words ≤ 3 ≤ 30 Long perspectives should be no more than 6000 words. Only commissioned by the Journal, but the editors also welmain text ≤ 6,000 words
- protocolThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
- reviewThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
- short communicationThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
- systematic reviewThe journal publishes Original Article, Review, Meta-Analysis, Systematic Review, Short Communication, Case Report, Protocol, Commentary, Perspective, Editorial…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Plagiarism, Preprints
- AI use AI and AI-assisted Technologies in Scientific Writing
For AI-assisted work, author(s) should not list AI or AI-assisted technologies as an author or co-author, nor cite AI as an author. AI and AI-assisted technologies cannot replace the tasks of researchers, such as developing scientific insights, analyzing and interpreting data, drawing scientific graphs, or drawing scientific conclusions. Author(s) should primarily use AI technologies to improve th…
Source ↗Publisher website ·- Authorship Authorship
The journal endorses the authorship criteria defined by ICMJE. Individuals who fulfill the following criteria can be defined as authors.
Source ↗Publisher website ·- Conflicts of interest Conflicts of Interest
Authors should provide a statement to disclose any potential or existing conflict of interest. The corresponding author must ensure that all authors have been asked to disclose any conflict of interest.
Source ↗Publisher website ·- Publication ethics Publication Ethics
Research EthicsFor any study involving human subjects, authors should provide a statement to state that the study is approved by an institutional ethics. Written informed consent to participate should be obtained from all participants. For manuscripts involving privacy issues (e.g., including individuals’ details in images or videos), authors must obtain the consent to publication from the partici…
Source ↗Publisher website ·- License & copyright Copyright and License to Publish
Journal articles are published under the CC BY license. Authors retain the copyright and full publishing rights without restrictions and agree to make their original works completely available and free to use, copy and/or redistribute in all formats without permission, as long as the authors and the original source are properly cited. A copyright statement is published on full text files including…
Source ↗Publisher website ·- Open access Open Access
Exploration of Targeted Anti-tumor Therapy is an open access journal and all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.
Source ↗Publisher website ·- Peer review Peer Review
Single-blind peer review; reviewers' identities concealed from authors, authors' identities known to reviewers. Model summary
The journal adopts a single-blind peer review model meaning that reviewers’ identities are kept concealed from authors, but authors’ identities are known to reviewers. All accepted articles (except for some Editorials released by the Editors) will have undergone a rigorous and thorough review process to evaluate their novelty, scientific content, academic integrity, etc. For more information on Pe…
Source ↗Publisher website ·- Plagiarism Plagiarism
Plagiarism is not acceptable and includes, but is not limited to, copying or reusing text, ideas, images or data from other sources without clear attribution, and goes against the principle of academic publishing. Reuse of parts of text from an author’s previous research publication without clear attribution is a form of self-plagiarism.
Source ↗Publisher website ·- Preprints Preprint Policy
The journal allows authors to post preprints of the Original Version, Accepted Manuscript, and Version of Record, on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Readers should visit Sherpa Romeo to view our preprint policy. For detailed information on our preprint policy, p…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Open Exploration Publishing Inc.
- Country or region
- China
- Language
- English
- ISSN
- 2692-3114
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Exploration of Targeted Antitumor Therapy
How long does peer review take at Exploration of Targeted Antitumor Therapy?
Based on the dates recorded on 96 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 101 days (interquartile range 76–121 days); authors report an average review time of about 13 weeks; the journal's website gives an acceptance rate of 33%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Exploration of Targeted Antitumor Therapy?
According to the journal's author guidelines: Abstract: ≤ 300 words; Keywords: 3–8; Manuscript length: ≤ 3,000 words; Reference style: Vancouver; Templates: Word; Suggested reviewers: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Exploration of Targeted Antitumor Therapy based?
Of the 65 board members whose country the journal's board page names, 12 (about 18%) are in mainland China; the countries named most often are Italy (21), Mainland China (12) and United Kingdom (7). Counted from the institutions listed on the board page; for reference only.
Which databases index Exploration of Targeted Antitumor Therapy?
According to LetPub and DOAJ records, Exploration of Targeted Antitumor Therapy is indexed in Scopus and DOAJ. The journal's website also lists PubMed; that list has not been checked against each database.
Is Exploration of Targeted Antitumor Therapy open access, and what is the APC?
Exploration of Targeted Antitumor Therapy is a fully open-access journal. APC about USD 2,000.
Sources and updates
The facts on this page come from LetPub, Publisher website, DOAJ, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .